{"id":"W2993666578","doi":"10.1182/bloodadvances.2019000966","title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":1336,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"National Heart, Lung, and Blood Institute; University of Oklahoma Health Sciences Center; National Institutes of Health; University of Oklahoma","keywords":"Medicine; Guideline; Rituximab; Immune thrombocytopenia; Intensive care medicine; Clinical trial; MEDLINE; Randomized controlled trial; Dosing; Hematology; Family medicine; Pediatrics; Internal medicine; Immunology; Antibody; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02765874513328463,"score_gpt":0.3483066406333629,"score_spread":0.3206478955000782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}